People In The News | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina said in a filing with the US Securities and Exchange Commission this week that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He currently is senior VP at Forest Research Institute, and he previously was CMO at Kalypsys. He also has served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."